ICUCW — SeaStar Medical Holding Corporation
NASDAQ
$0.02
-$0.00 (-5.76%)
SeaStar Medical Holding Corporation (ICUCW) common stock listed on NASDAQ. It is led by Eric Schlorff, based in 3513 Brighton Boulevard, Denver, CO, United States, 80216, with about 17 employees. SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Latest reported ICUCW revenue for 2025-09-30 was $183.0K. Net income was -$3.5M. Revenue was down 45.9% from 2025-06-30 to 2025-09-30.
Use this ICUCW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ICUCW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ICUCW SEC filings page. Lician reads the product cache first so this HTML stays unique to SeaStar Medical Holding Corporation even when a live quote feed is slow.
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
ICUCW Key Statistics
Market Cap
$0.00M
Volume
6,822
Previous Close
$0.02
Day Range
$0.02 – $0.04
EPS
-$6.63
Revenue
$135.00K
Net Income
-$24.83M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-18392.6%
Employees
17
ICUCW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $135.00K | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$24.83M | -$26.23M | -$12.19M |
| EPS (Diluted) | -$6.63 | -$30.26 | -$1.48 |
Total Assets
$4.66M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.82M
Operating Cash Flow
-$16.01M
Free Cash Flow
$0.00
SeaStar Medical Holding Corporation Company Information
- CEO, Treasurer, President & Executive Director
- Eric Schlorff
- Headquarters
- 3513 Brighton Boulevard, Denver, CO, United States, 80216
- Website
- seastarmedical.com
- Phone
- 844 427 8100
- IPO / Founded
- 2021-03-18